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1. Introduction
Pharmacokinetics is the science of the kinetics of drug absorption, distribution, and elimination
(i.e., metabolism and excretion). Kinetics is the study of the rate of a process and the factors
affecting on it. The rate of a process is the change in velocity or speed with (in relation to) time.
Usually, pharmacokinetics study involves considering both experimental and theoretical
approaches. The former involves development of biologic sampling techniques, analytical
methods for drugs and their metabolites measurement, and procedures that help in data
collection and handling, while the latter approach of pharmacokinetics involves development
of pharmacokinetic models that facilitate prediction of drug disposition after drug adminis‐
tration [1].
For the processes of drug absorption, distribution, and elimination, there is a rate that governs
each process. The rate is the change in concentration with time and is given by ± dC/dt.
According to the law of mass action, the rate of a chemical reaction (or a kinetic process) is
proportional to the products of the molar concentration of the reactants each raised to a power
equal to the number of molecules of substances undergoing reaction (process).
• The rate expression for zero order reaction:
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Mostly, the pharmacokinetic processes (absorption, distribution, and elimination) are first-
order, although zero-order also accounts for some processes such as the process of absorption,
which is first-order for the passive transport mechanism and zero-order for the carrier-
mediated transport (1).
It must be mentioned that drug kinetics after distribution is characterized by the first-order
rate constant.
A compartment in pharmacokinetics is an entity that can be described by a definite volume and
a concentration of a drug contained in that volume, which may be:
1. Central Compartment
The central compartment includes blood and the highly perfused organs and tissues such as
heart, brain, lungs, liver, and kidney. In these organs, the administered drug usually equili‐
brates rapidly.
2. Peripheral Compartment(s)
This compartment(s) include(s) those organs that are less well-perfused such as adipose and
skeletal muscle, and therefore the administered drug will equilibrate more slowly in these
organs. The duration of the drug effect at the target tissue will often be affected by the
redistribution from one compartment to another. For example, the general anesthetic drug,
thiopental, which is a highly lipid-soluble agent, induces anesthesia within seconds owing to
drug rapid equilibration between blood and brain. The duration of anesthesia is short due to
drug redistribution into adipose tissue, which can act as a storage site, or drug reservoir,
although thiopental is slowly metabolized.
3. Special Compartments
Drug access to some body parts such as the cerebrospinal fluid (CSF) and central nervous
system (CNS) is controlled by the structure of the CNS blood capillaries and the outermost
layer of the neural tissue, i.e., pericapillary glial cells (the choroid plexus is an exception). Also,
some drugs have relatively poor access to pericardial fluid, bronchial secretions, and fluid in
the middle ear, thus making the treatment of infections in these regions difficult. These special
compartments deserve mention as a separate category.
A pharmacokinetic model is a model devised to simulate the rate process of drug absorption,
distribution, metabolism, and elimination with little physiological detail.
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During development and formulation of pharmaceutical dosage forms and drug delivery
systems, an interrelationship between these dosage forms/drug delivery systems and bio‐
pharmaceutical principals must be established to ensure clinical application of these dosage
forms in patient care [2]. Drugs may be introduced into the body via some routes that involve
an absorption phase such as oral, topical, intramuscular, subcutaneous, nasal, pulmonary and
rectal. For intramuscular, and subcutaneous routes of administration, the absorption is
uncomplicated and there is less variability in the absorption process and hence the bioavaila‐
bility is often considered close to 100%. Drugs that are administered by intravascular route
(Intravenous and intrarterial) do not involve an absorption step [3]. Assesment of bioavaila‐
bility could be achieved from plasma data, urine data, acute clinical response and clinical trials
[3].
When a drug is administered into the body, it will distribute into the different organs and body
compartments. Analysis of the drug kinetic in the body may be compartmental or non-
compartmental. The former is used to describe the drug disposition (distribution and elimi‐
nation) and the drug concentration in plasma and highly perfused organs assuming that
changes in drug plasma concentration are equivalent with that in tissue concentration and the
elimination process is achieved from central compartment. The later is used to identify certain
pharmacokinetic parameters without deciding on a particular compartmental model. The
basic calculations are based on the area under the plasma concentration versus times curve
(zero moment) and the first moment curve (AUMC).
2. One-Compartment Open Model: Intravenous Bolus Administration
This model represents the simplest way to describe the process of drug distribution as well as
elimination in the body. In this model, the body acts like a single, uniform unit in which the
drug can enter or leave the body easily (i.e., the model is “open” for the drug movement).
For IV bolus administered drugs, the entire dose enters the bloodstream directly. This is
followed by distribution of the drug through the circulatory system to all the tissues in the
body. Concentration of the drug in various tissue organs or the process of drug distribution
in the body will occur depending on the blood flow to the tissue, the molecular weight of the
drug, the drug lipophilicity, plasma protein binding, and the binding affinity of the drug
toward certain tissue.
Mostly, drugs are eliminated from the body either through the kidney and/or the liver
following drug metabolism.
The first pharmacokinetic parameter that arises in this model is the apparent volume of distri‐
bution, VD, which is the volume in which the drug is distributed on it within the body, while
the elimination rate constant, k, is the second pharmacokinetic parameter in this model, which
governs the rate at which the drug concentration in the body declines over time.
A representative diagram that describes this model is illustrated below:
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  k 
IV dose ----------------------˃ DB, VD -------------------˃ elimination 
odel does not give information about the actual drug levels in the body tissues. However, 
This model does not give information about the actual drug levels in the body tissues.
However, the model assumes that any changes in the plasma drug levels will always result in
a relative change in tissue drug levels.
The general equation that describes this model is:
 /        .       –  . / 2.303o kel t o ep ldC dt k Cp and Cp Cp e and log Cp log Cp k t= - = =
 Or /       .  ,     –  . / 2.303o kel t oB B B B B eldD dt k D and DB D e So log D log D k t= - = =
2.1. Elimination Rate Constant
For most drugs, the process of drug elimination is a first-order rate process, i.e., the process is
dependent on the amount or concentration of drug present, and the unit of the elimination
rate constant k is time–1 (e.g., hr–1 or 1/hr).
Total removal or elimination of the parent drug from this compartment is effected by metab‐
olism (biotransformation) and excretion. So, this constant represents the sum of these two
processes:
    k km ke= +
A rate expression for the first-order elimination is:
/     B BdD dt k D= -
Integration of the above equation gives the following expression:
0   k tB BD D e=
The last equation can also be expressed in the logarithmic form as:
0   –   / 2.303B BLog D log D k t=
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Figure 1. Linear Plot of Cp versus Time for a One-Compartment IV Bolus
Figure 2. Semilog Plot of Cp versus Time
2.2. Apparent Volume of Distribution
The volume that must be considered in estimating the amount of drug in the body from the
concentration of drug found in the sampling compartment is referred to as volume of distribu‐
tion. This volume does not represent a physical space in the body but it is a dilution space. In
other words, it is a theoretical volume that represents the distribution of the administered drug
between the plasma and the rest of the body following administration of the medicament.
To predict the volume of distribution we must assume that the amount of the drug in the body
(DB) is the function of both the concentration of the drug in the plasma (CP) and the volume of
fluid the drug is distributed in.
Since; DB =  VDCP
Assuming DB is the IV dose
( )     /  BVD IV dose D Cp=
The amount of drug in the body is estimated by taking a blood sample at periodic intervals
and analyzing for the concentration of drug present. So, it is not determined directly.
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Similar expression based on drug concentration in plasma is obtained for the first-order decline
of drug plasma levels:
   –    /  2.303P PLog C log C k t=
2.2.1. Calculation of Volume of Distribution
This pharmacokinetic parameter, volume of distribution (V D), is calculated in the one-
compartment model (IV administration) using the following equation:
0 0 0   /   /  D P B PV IV dose C D C= =
Since the rate of drug elimination is: d DB /  dt  =  −k  DB
substitution of DB =  VDCP  ; so, d DB /  dt  =  −k  VDCP
Rearrangement of the equation: d DB =  −  k  VDCPdt
Integration of the last equation and assuming AUC is the summation of the area under the
curve from t=0 to t= α:
0 0  DD k V AUC
aé ùë û=
Thus, the apparent VD may also be obtained from knowledge of the dose, elimination rate
constant, and the area under the curve (AUC) from t = 0 to t = ∞:
0 0 /   DV D k AUC
aé ùë û=
N.B: The AUC∞ 0 is usually estimated by the trapezoidal rule.
2.2.2. Significance of the Apparent Volume of Distribution
Assuming the following equation:
0 0 0   /   /  D P B PV IV dose C D C= =
The apparent VD is dependent on Cp0. Drugs characterized by a large apparent VD are mainly
concentrated in extravascular tissues and are less concentrated in the intravascular capillaries.
In case of drugs that are highly bound to plasma proteins or remain in the vascular capillaries,
as for highly hydrophilic drugs, the Cp0 will be high and this is resulting in a smaller VD.
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It must be mentioned that the apparent volume of distribution is not a true physiologic volume.
This pharmacokinetic parameter is useful in considering distribution and the relative amounts
of drug in both vascular and extravascular tissues.
2.3. Clearance
Clearance or drug clearance is a pharmacokinetic term describing the process of drug elimina‐
tion from the body without identifying the mechanism of the process. It refers to the volume
of plasma fluid that is cleared of drug per unit time (volume approach, L/hr or mL/hr) or the
amount of the drug eliminated from the body per unit time (mass approach, mg/min or mg/
hr). It may also be considered as the fraction of the drug VD that is excreted by the kidney per
unit time (fraction approach). It must be mentioned that a constant volume of plasma (about
120 mL/min in humans) is filtered through the glomeruli of the kidneys. For drugs that exhibit
significant plasma protein binding, clearance is related to the total drug concentration in the
plasma (free + protein-bound) and not the free concentration [5].
For drugs that are eliminated by first-order elimination process, the elimination rate is not
constant and changes with respect to the drug concentration in the body, and hence, the drug
clearance is expressed as volume per unit time (e.g., L/hr or mL/min). This is convenient
because the volume per unit time is a constant, whereas for drugs that are eliminated from the
body by a zero-order elimination process, expressing the rate of drug elimination as mass per
unit time is convenient because the clearance rate is constant and does not depend on the drug
plasma concentration.
Mathematically, since the rate of drug change (elimination) in the body is dependent on the
drug plasma concentration CP,
d DB /  dt  =  −  k  DB and since DB =  VDCP
so, d DB /  dt  =  −  k  VDCP
Dividing the above equation by CP,
d DB /  dt /  CP =  −  k  VDCP /  CP  ; then, d DB /  dt /  CP =  −k  VD =  − clearance
The term [dDB/ dt]/ CP in the above equation is considered clearance according to the fraction
approach.
The term fraction of total drug eliminated is applicable and convenient during expressing drug
elimination whether one is dealing with an amount or a volume because of its dimensionless
nature.
2.4. Calculation of 'k' from Urinary Excretion Data
Assuming the excretion rate of the drug is first-order, the elimination rate constant k may be
calculated from urinary excretion data. The term ke is the renal excretion rate constant, and Du
is the amount of drug excreted in the urine.
d Du / dt  =  keDB, DB can be substituted for DB0e −kt
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So, d Du / dt  =  keDB0e −kt
and log  d Du / dt  =  log  keDB0 –  kt / 2.303
Plotting log dDu /dt versus time on regular paper or on semilog paper dDu/dt against time results
in a straight line in which the slope of this curve is equal to –k/2.3 and the y intercept is equal
to ke D B0. If DB 0 is known, the renal excretion rate constant (ke) can be obtained.
For nonrenal rate constant (k nr), i.e., for any route of elimination other than renal excretion, it
could be estimated from: k – ke = knr
N.B: Experimentally, it is difficult to determine the drug urinary excretion rate (dDu / dt) and
it is more convenient to plot the average rate of urinary drug excretion (Du/tinterval) against the average
time t* for the collected urine samples. Du/t is the amount of drug excreted divided by the time
interval.
Practice Example
A single intravenous dose of an antibiotic was administered to a 50-kg woman at a dose level
of 20 mg/kg. Samples of urine and blood were removed periodically and assayed for parent
drug. The following data were obtained:
Time (hr) Cp (µg / ml) Du (mg)
0.25 4.2 160
0.50 3.5 140
1.0 2.5 200
2.0 1.25 250
4.0 0.31 188
6.0 0.08 46
Solution
Here t* = midpoint of collection period; and t = time interval for collection of urine sample.
To solve this problem, first plot on a semilogarithmic scale the relation between Du / t versus
t*. A straight line is obtained; the slope of this line should equal –k/2.3. Then, determine the
elimination t½ directly from the curve and calculate k from the first-order equation k = 0.693/t½
Time (hr) Du (mg) Time Interval Du/t (mg / hr) t*
0.25 160 0–0.25 = 0.25 160/0.25 = 640 (0+ 0.25)/2 = 0.125
0.50 140 0.5–0.25 = 0.25 140/0.25 = 560 (0.25 + 0.5)/2 = 0.375
1.0 200 1–0.5 = 0.5 200/0.5 = 400 (0.5 + 1) /2 = 0.750
2.0 250 2–1 = 1 250/1 = 250 (1+2)/2 = 1.5
4.0 188 4–2 = 2 188/2 = 94 (2+4)/2= 3
6.0 46 6–4 = 2 46/2 = 23 (4+6)/2= 5
In this example, t½ = 1.0 hr and k = 0.693 hr– 1.
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The sigma-minus method, or the amount of drug remaining to be excreted method, is an alternative
method for calculation of the elimination rate constant k from urinary excretion data is. This
method is sometimes preferred over the previous method since minimum fluctuations in the
rate of elimination is obtained by this method.
If the amount of unchanged drug that is ultimately excreted in the urine is D∞u and, Du is the
cumulative amount of unchanged drug excreted in the urine at a specific time. The amount of
the drug remaining to be excreted is D∞u - Du, in which the rate of excretion of this amount is
dependent on or proportional to D∞u as the process is a first-order and so,
 . k tu u uD D D e¥ ¥ -- =
The last equation can be written in the logarithmic form as:
     /  30( 2.) 3u u ulog D D log D kt¥ ¥- = -
This equation describes the relationship for the amount of drug remaining to be excreted
(D∞u – Du) versus time.
A linear curve is obtained by plotting on a semilog paper the amount of the drug unchanged
yet to be eliminated, log (D∞u – Du) versus time, the slope of this curve is –k/2.3, and the y
intercept is D∞u.
Practice Example
Using the data in the preceding problem, determine the elimination rate constant.
Time (hr) Cp (µg / ml) Du (mg)
0.25 4.2 160
0.50 3.5 140
1.0 2.5 200
2.0 1.25 250
4.0 0.31 188
6.0 0.08 46
Solution
Time (hr) Du (mg) Cumulative Du D∞ u – Du
0.25 160 160 984–160 = 824
0.50 140 160 + 140 = 300 984–300 = 684
1.0 200 300 + 200 = 500 984–500 = 484
2.0 250 500 + 250 = 750 984–750 =234
4.0 188 750 + 188 = 938 984–938 = 46
6.0 46 938 + 46 = 984 984–984 = 0
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Plot log (D∞u – Du) versus time. Use a semilogarithmic scale for (D∞u – Du). Evaluate k and t½
from the slope.
3. Multicompartment Models: Intravenous Bolus Administration
3.1. Introduction
It was observed that the plasma-level time curve for some drugs following its rapid IV injection
does not decline linearly as a single, first-order rate process. This nonlinear plasma-level time
curve is attributed to distribution of these drugs at various rates into different tissue groups.
So, these multicompartment models were developed to explain and also to predict the plasma
and tissue concentrations of these drugs. Again, drug distribution in the body depends mainly
on plasma protein binding, tissue affinity, and drug lipo- or hydrophilicity.
It must be mentioned that the kinetic description of the multicompartment process assumes
that the rate of drug transfer between central and tissue compartments is first-order.
It is noteworthy to mention that the body can be divided into organs with high blood perfusion
and those with slow blood perfusion. The heart, brain, liver, lungs, kidney, endocrine glands,
skin and muscle, adipose tissue, and marrow, which account for 78% of the body weight, are
highly blood-perfused organs, while bones, ligaments, tendons, cartilage, teeth and hair which
comprise the remaining 22% of the body weight are slowly blood-perfused.
The central compartment consists of the plasma, extracellular fluids and highly perfused
tissues in which drug equilibrate rapidly. The kidney and liver, which are the tissues for drug
elimination, are considered integral parts of the central compartment.
3.2. Two-Compartment Open Model
The plasma-level time curve for a drug that follows a two-compartment model shows that the
plasma drug concentration declines biexponentially as the sum of two first-order processes—
distribution and elimination. This is attributed to distribution of the administered drug
between the central compartment and tissue (peripheral compartment).
k12 
k21 
  
Central compartment 
DP  VP  CP 
Tissue compartment 
Dt  Vt  Ct 
Figure 3. Figure shows distribution of the administered drug between central and peripheral compartment
Construction of the plasma-level time curve for a drug that follows a two-compartment model
indicates that the curve may be divided into two phases: a distribution phase and an elimina‐
tion phase. At t = 0, no drug is in the tissue compartment and hence, the distribution phase of
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the curve begins and represents the initial, more rapid decline of drug from the central
compartment into the tissue compartment. Later, the drug starts to enter the tissue (peripheral
compartment) and when the drug reaches the maximum tissue concentrations, an equilibrium
is established and the rate of drug entry into the tissue equals the rate of drug exit from the
tissue. At this stage, the drug concentrations in the central and tissue compartments will
decline in a parallel and slower manner when compared to the distribution phase. This phase
is the elimination phase and the decline is a first-order process.
For most two-compartment models the elimination occurs from the central compartment
model unless other information about the drug is known since the major sites of drug elimi‐
nation (renal excretion and hepatic metabolism) occur from organs such as the kidney and
liver, which are highly perfused with blood [6, 7].
If k12 and k21 are first-order rate constants that govern the rate of drug change in and out of the
tissues, then the change in drug concentration in the tissue with time could be calculated from
the following equation:
12 21/   –  t t P tdC d k C k C=
And since CP =  DP /  VP  andCt =  Dt /  V t
then dCt /  dt =  k12DP /  VP −  k21Dt /  V t
where Dp represents the amount of drug in the central compartment, D t is the amount of drug
in the tissue compartment, V p represents the volume of drug in the central compartment, and
V t is the volume of drug in the tissue compartment.
The mathematical expression that best describes the two-compartment IV bolus is:
– .  .at btPC A e B e-= +
The constants a and b represent the rate constants for the two phases, distribution phase and
elimination phase, respectively. The constants A and B are intercepts on the y axis obtained
from the plasma-level time curve after IV bolus, which exhibit two compartments. These values
may be obtained graphically by the method of residuals or by computer.
Figure 4. Semilog plot of plasma-level versus time for a two-compartment IV bolus model
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3.2.1. Method of Residuals
This method is used for fitting curve into the experimental data when the drug does not follow
a one-compartment model. The method is sometimes called Feathering or Peeling method.
Practice Example
A 70-kg patient was administered a drug by rapid IV injection in a dose of 100 mg. Blood
samples were taken periodically after the administration of drug, and the plasma samples were
assayed for the drug concentration. The following data were obtained:
Time (hr) Plasma Concentration (µg/ml)
0.25 43
0.5 32
1 20
1.5 14
2 11
4 6.5
8 2.8
12 1.2
16 0.52
If you plotted the provided data on semilogarithmic graph paper, a curved line is observed
which indicates that the drug is distributed in more than one compartment.
From the data, the constants may be obtained either by the computer or by the method of
residuals, in which the equation that describes the process is:
–    at btPC A e B e-= +
Plotting of the data indicates that the curve is biexponential: the first segment for the distri‐
bution phase (rapid phase), while the second for the elimination phase. The rapid distribution
phase is confirmed when comparing the values for a and b, the constant a being larger than
the rate constant b. Therefore, at some later time, the term Ae–at will approach zero, while Be–
bt will still have a value. At this later time, the two-compartment IV bolus equation will reduce
to:
  btPC B e-=
 latw tPC B e b-= gg
And the logarithmic form is:
Basic Pharmacokinetic Concepts and Some Clinical Applications
    / 2.303.PlogC log B bt= -
It is possible to calculate the rate constant b from the slope (–b/2.3) of a straight line representing
the terminal exponential phase in which b was found to be 0.21 hr -1. The t½ for the elimination
phase (beta half-life) can be derived from:
½  0.693 /  t b=
The regression line for the terminal phase could be extrapolated to the y axis, in which the y
intercept is equal to B, or 15 µg/mL.
Figure 5. Semilog Plot of Cp versus Time Showing Cplate
To obtain the constant a, the values for the drug plasma concentrations at the extrapolated line
are subtracted from the original experimental data point to get the residual plasma concen‐
tration. Plotting the values of the residual plasma concentrations versus time will yield a
straight line that represents the rapid distribution (a) phase. The slope of the line (-a /2.3) and
the value of (a) is 1.8 hr-1, and the y intercept is 45 µg/mL.
Time (hr) Plasma Concentration
(µg / ml)
Extrapolated Plasma
Concentration C’P
Residual Plasma
Concentration CP - C’P
0.25 43 14.5 28.5
0.5 32 13.5 18.5
1 20 12.3 7.7
1.5 14 11 3
2 11 10 1
4 6.5
8 2.8
12 1.2
16 0.52
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Figure 6. Semilogplot of Cp versus time showing residual line
A number of pharmacokinetic parameters may be derived by proper substitution of rate
constants a, b, and y intercepts (A and B) into the following equations:
( ) ( ) ( ) ( )212    /    ,   /     k ab A B Ab Ba k AB b a A B Ab Ba= + + = - + +
21     /    k Ab Ba A B= + +
3.2.2. Apparent Volumes of Distribution
As mentioned previously, drugs with extravascular distribution such as those with high
peripheral tissue binding contribute to a large apparent volume of distribution, while drugs
that are polar with low lipid solubility or which highly bound to plasma protein account for
small apparent VD.
In multiple-compartment kinetics, such as the two-compartment model, several volumes of
distribution can be calculated.
3.2.3. Volume of the Central Compartment (At Zero Time)
It is important to mention that the adult person has around 5L blood; 45% of this volume is
cellular part and 55% noncellular part, of which 90% of the noncellular part is plasma, and so
the volume of plasma in the central compartment is approximately greater than 3 L.
For many polar drugs, an initial volume of 7–10 L may be interpreted as rapid distribution of
the administered drug within the plasma and some body extracellular fluids. For example, the
Vp of the antibiotic moxalactam ranges from 0.12 to 0.15 L/kg, corresponding to about 8.4 to
10.5 L for a typical 70-kg patient.
In the two-compartment model, if we multiply the drug concentration by the volume of the
fluid, it must equal to the dose at time zero since D0 = Vp Cp. If this is true, then the volume of
distribution will equal 3 L and if not, then distribution of drug may also occur outside the
vascular pool.
The apparent volume of the central compartment is:
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 / op oV D Cp=
Do is the entire amount of the drug in the body which is equivalent to the IV dose while, Cpo
is the initial concentration of the drug in the central compartment or the concentration at time
= zero.
At zero time (t= 0), the total drug in the body is in the central compartment. C0p will equal to
A + B by the following equation:
–  .  .at btCp A e B e-= +
At t = 0, e0 = 1 and so, Cp =  A +  B
And so, Vp =  Do /  A + B
Instead, the volume of the central compartment Vp may be calculated from the area under the
curve [AUC]α 0 in a manner similar to the calculation of the apparent VD in the one-compart‐
ment model.
0  /o DAUC D kV
a =é ùë û
In contrast, [AUC] α 0 for the two-compartment model is Do / k VP
And so,
0  /oVp D k AUC
aé ùë û=
3.2.4. Apparent Volume of Distribution at Steady-State
When the rate of drug entering the peripheral (tissue) compartment from the central com‐
partment is equal to the rate of drug exit from the tissue compartment into the central
compartment, this condition is achieved at steady-state and the rates of drug transfer between
the two compartments are described by the following expressions:
21 12 t pD k D k=
12 21 /  t pD k D k=
Since the amount of drug in the central compartment, Dp, is equal to Vp Cp,
so, Dt =  k12VpCp /  k21
Assuming a steady-state condition is reached, therefore the apparent volume of drug distri‐
bution at steady-state (VD)ss may be determined by dividing the total amount of drug in the
body by the concentration of drug in the central compartment at steady-state:
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( )   /  D p t pSSV D D C= +
( ) 12 21  /   /  D p p p p pSSV V C k V C k Cé= ùë û+
( ) 12 21  /  D p pSSV V k k V= +
3.2.5. Volume of Distribution by Area
The volume of distribution by area, also known as (VD)area, or simply (VD), is obtained by a
method similar to that used to find Vp, except that the rate constant b is used instead of the
overall elimination rate constant k. This is achieved through dividing the total body clearance
by b and is influenced by drug elimination in the beta, or b, phase.
So, the reduction in drug clearance from the body may increase the area under the curve AUC,
which is reflected on the value of (VD) that is either reduced or unchanged depending on the
value of b.
( ) ( ) 0  /  . D D oareaV V D b AUC ab = é ùë û=
Since total body clearance is equal to Do / AUC 0∞,
so, (VD)β =clearance / b =kVp / b
Here the volume of distribution is related to the body clearance, and the body clearance usually
occurs during the elimination phase.
Example
The first two columns of the provided table represent the time and plasma concentration,
which may be collected after IV bolus administration of 500 mg of drug.
Time (hr) Plasma Concentration
(mg/ml)
Extrapolated Plasma
Concentration
C’P
Residual Plasma Concentration
CP - C’P
0.25 20.6 8.8 11.8
1 13.4 7.8 5.6
2 7.3 6.1 1.2
3 5 4.7 0.3
4 3.7 3.7 -
6 2.2
8 1.4
10 0.82
12 0.5
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If these data are plotted, the following figure 7 is obtained:
Figure 7. Plot of Cp versus Time Illustrating the Method of Residuals
At t = 0 gives B = 10 mg/L. From the slope of the line β = 0.25 hr-1. C extrapolated values at early
times are shown in column 3 and the residual in column 4. The residual values are plotted
again, giving a value of A = 25 mg/L and α = 1.51 hr-1. Note that α/β = 6; thus, these values
should be fairly accurate.
( ) 1  10 / ,    10   0.5 / 12  2.996 / 12  0.25 B mg L ln ln hrb -= = - = =
( ) 1  25 / ,    25   0.27 / 3  4.528 / 3  1.51 A mg L ln ln hra -= = - = =
Therefore Cp =  25 ⋅  e −1.51 ⋅ t +  10 ⋅  e −0.25 ⋅ t
1
21
25 0.25 10 1.51 0.6125 10
A Bk hrA B
b a -+ ´ + ´= = =+ +
g g
1
21
1.51 0.25 0.620.61elk hrk
a b -´= = =g
1
12 21 1.51 0.25 0.61 0.62 0.53elk k k hra b -= + - - = + - - =
1
500 14.335
DoseV LA B= = =+
500 34.30.25 58.3area
DoseV LAUCb= = =´g
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21 12
1
21
0.61 0.6214.3 26.70.61ss
k kV V Lk
+ += = ´ =
3.2.6. Drug Clearance
The concept for drug clearance that follows a two-compartment model is similar to that of the
one-compartment. Clearance may be calculated without consideration of the compartment
model. Clearance is calculated by dividing the IV bolus dose by the area under the plasma-
level time curve from zero to infinity.
 /  l o oC D AUC
aé ùë û=
The last equation could also be expressed as a function of volume of distribution:
Since (VD)β =  Do /  b. AUC α0
So, Cl =  (VD)βb
The last equation is simple and gives more accurate results than using the trapezoidal rule to
obtain area.
4. Intravenous infusion
4.1. Introduction
Drugs administered by IV route may either be given at once (as a bolus dose) or by slower IV
infusion over a definite time such as Phenytoin which must be given slowly, no greater than
50 mg/min (and preferably 25 mg/min or less) in adults. Such drugs are infused slowly through
a vein into the blood at a constant rate (zero order input) which allows precise control of plasma
drug concentrations.
The following figure represents the plasma-level time curve for a drug given by constant IV
infusion. At time zero, no drug was present in the body after which the drug level gradually
increases until it becomes constant (plateau or steady-state). Once the drug has reached the
steady-state, the rate of drug leaving the body is equal to the rate of drug entering the body.
The mathematical expression or the pharmacokinetic equation for drug administered by
infusion will depend on whether the drug follows the one- or two-compartment model.
4.2. One-Compartment IV Infusion
Drugs administered by constant IV infusion show a zero-order input process, during which
the drug is introduced into the bloodstream while the elimination process for most drugs is
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first-order. The rate of input minus the rate of output represents the change in the amount of
drug in the body at any given time (dDB/dt) [1].
Figure 9. Plasma-concentration time curve after IV Infusion
If DB is the amount of the drug in the body, R is the rate of drug input (infusion rate) and k is
the elimination rate constant. The expression that best describes the process is:
/    –   B BdD dt R k D=
/    –   B P DdD dt R k C V=
Integration of the last equation will give:
Figure 8. Plasma-concentration time curve during the infusion of the administereddrug at constant rate
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( ) /  1  ktP DC R V k e-é ùë -û=
At infinite time, t = α and e –kt will approach zero (at steady-state) and the last equation will
be:
  /   / ClearanceDCss R V k R= =
N.B:
1. At steady-state, the rate of drug input (R) is equal to the rate of drug output (k DP),
so, R =  k  DP  and R =  k . CP . VDCP =  R / VD. k
At steady-state, CP = Css
So, R =  k  CssVDCss =  R /  k .VDCss =  R / Cl
2. Once the infusion stops either this achieved at or before steady-state is reached, the drug
concentration will decline according to first-order rate kinetics with the slope of the
elimination curve that is equal to –k/2.3.
Example
A desired steady-state plasma concentration of theophylline may be 15 mg/L. The average
half-life of theophylline is about 4 hr and the apparent volume of distribution is about 25 liter.
What is the necessary infusion rate?
From the t ½, kel or k = 0.693/4 = 0.17 hr-1
     15  0.17  25  63.75 mg/hrDR Css k V x x= = =
4.2.1. Steady-State Drug Concentration (CSS) and Time to Reach Steady-State
During administration of a drug by IV infusion, the plasma drug concentration starts to
increase and the rate of drug elimination will also increase since the latter is concentration-
dependent. Cp keeps increasing until a steady-state condition is reached at which the rate of
drug input (IV infusion rate) equals the rate of drug output (elimination rate). At this stage, a
steady-state (CSS) is reached and the resulting plasma drug concentration is directly related to
the rate of infusion and inversely related to the body clearance of the drug.
For drug administered by IV infusion, the therapeutic activity is observed when the concen‐
tration of the drug is close to the desired plasma concentration, which is usually the required
steady-state drug concentration.
The time to reach steady-state could be determined by knowing the time to reach half the
steady-state which can be derived:
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Since Css =  R / VDk  =  R / Clearance
At (t½); time to reach half the steady-state CP = Css/2
( )–   / .  1    / 2k tP D half ssC R V k e Cé ùë= - =û
( )–   1    / 2k tP ss half ssC C e C= - =
( )–  1    / 2k tss half ssC e C- =
–  1   ½k thalfe- =
–    ½  1k thalfe- = -
–   0.5k thalfe =
Taking the ln to both sides, thalf =  0.693 / k
It must be noticed that the time to reach half the steady-state has the same value for the
elimination half-life and is dependent on the elimination process not the infusion rate while
the value of Css is controlled by the infusion rate. An increase in the infusion rate will not
shorten the time to reach the steady-state drug concentration.
From the pharmacokinetic point of view, for drugs administered by IV infusion, the clinical
effect of the drug (activity) is observed when the drug concentration in the plasma is close to
the desired plasma drug concentration, which is the desired steady-state drug concentration.
Examples
1. A drug belonging to the cephalosporins antibiotics has a volume of distribution of 10 L
and an elimination rate constant (k) value of 0.2 hr– 1. A steady-state plasma concentration
of 10 µg/mL is desired. What is the infusion rate required to maintain this concentration.
( )  . .   10  10  1000   0.2  20 mg/hrss DR C V k R x x x= = =
2. A septicemia patient was administered by constant IV infusion an antibiotic that has an
elimination half-life (t½) of 6 hr. The rate of infusion was 2 mg/hr. At the end of second
day of treatment, the serum drug concentration was 10 mg/L. Calculate the total body
clearance ClT for this drug.
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 /  /   2 / 10  200 ml/hrss l l ss lC R C C R C C= = = =
3. An infinitely long period of time is needed to reach a steady-state level of a certain drug.
However, in clinical practice it is quite acceptable to reach 99% of the steady-state level
(99% Css). Calculate a time required to reach steady-state relative to the half-life of this
drug.
( )  /   1  ktP DC R V k e-é -ùë û=
At 99% steady-state, CP =  99% Css =  99% R / VDk
So, R /  VDk  (1−  e −kt) =  99% R / VDk
–1   99%kte- =
Taking the natural logarithm, ln 0.01=  −  kt
99%   0.01 /    4.69 /sst ln k k= - =
Substitution for k = 0.693/ t ½
( )99% ½ ½ 4.61 /  0.693 /    6.65 sst t t= =
Accordingly, as a general example, if the t½ for a drug is 6 hr, the time needed to reach 90%,
95%, and 99% of the steady-state is to be calculated. So, at those concentrations, 10%, 5%, and
1% respectively dropped from the total will take 3.32, 4.32, and 6.65 half-lives. Thus, the time
for a drug whose t½ is 6 hr to reach at least 95% of the steady-state plasma drug concentration
will be 5 t½, or 5 x 6 hr = 30 hr. Also, for theophylline with a t½ equal to 4 h, the time to reach
94% of steady-state will be 16 hr.
4.2.2. Calculating Patient Elimination Half-Life Following Drug Infusion
The half-life for drug administered by IV infusion could be calculated from (0.693/k). So, a
mathematical expression that describes the elimination rate constant should first be deter‐
mined.
( ) /  1  ktP DC R V k e-é ùë -û=
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And since Css =  R / kVD
( )  1  ktP ssC C e-é ù -ë û=
–  . ktP ss ssC C C e= -
–.   ktss ss PC e C C= -
( )–  –  /kt ss sse C Cp C=
( )/ 2.303   –  /ss sskt log C Cp C=
( )  2.303 / .  –  /ss ssk t Log C Cp C= -
It is noteworthy to mention that knowing the half-life for the administered drug in the general
population helps to determine if the sample is taken at steady-state in the patient, and after
administration of the drug by the IV infusion, one or two plasma samples must be taken at a
known time to compare.
Examples
A patient was administered an IV infusion of a certain antibiotic at an infusion rate of 15 mg/
hr. Blood samples were taken from this patient at 8 and at 24 hr and the plasma concentrations
for this drug were found to be 5.5 and 6.5 mg/L, respectively. Calculate approximately the
elimination half-life of this drug.
N.B: The antibiotic has an elimination half-life of 3–6 hr in general population.
Answer
Assuming the extreme case of t½ (6 hr), the second plasma sample was taken at 24 hr, or 24/6
= 4 half-lives after infusion, which is supposed to be near the theoretical time for steady-state.
( ) ( )  2.303 /   –  /    2.303 / 8   6.5 –  5.5 /  6.5ss p ssk t log C C C k log= - = -é ù é ùë û ë û
1
½  0.234  0.693 / 0.234  2.96 k hr t hr-= = =
In the previous example, if we desire to let the steady-state plasma concentration equal 8 mg/
L, what is the suitable infusion rate?
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Answer
First from the old data, we should calculate the clearance rate:
  /   15 /  6.5  2.31 /l lCss R C C L hr= = =
Then, for the new infusion rate R =  Css x Cl  =  8 x 2.31 =  18.48 mg / hr
4.2.3. Loading Dose plus IV Infusion (Combined Infusion and Bolus Administration)
If we desire to achieve a quick therapeutic concentration, a loading dose by rapid intravenous
injection (bolus injection) is first administered and then starts the slower maintenance infusion.
At this condition, the total drug concentration in the plasma is the function of both; the IV
bolus and the infusion doses.
The concentration following IV bolus (C1) is described by:
( )– –1   Loading Dose /kt kto L DC C e D V e= =
The concentration following IV infusion at rate R is:
( )–2  / 1  ktDC R V k e= -
The total concentration Cp will be the sum of bolus and infusion:
1 2  PC C C= +
( )– – /  / . 1  kt ktP L D DC D V e R V k e= + -
( )– –Or,  /   /  . –  / . kt ktP D L D DC R V k D V e R V k e= +
If the loading dose (DL) represents or equals the amount of drug in the body at steady-state,
so,  .    / ,  ,  .  /L ss D ss D ss DD C V and since C R V k so C V R k= = =
Therefore, DL =  R / k
Examples
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An anesthetic agent was administered by IV infusion at a rate of 2 mg/hr. The drug has an
elimination rate constant of 0.1 hr –1, and a volume of distribution (one compartment) equals
to 10 L. What loading dose is recommended if the physician wants the drug level to reach 2
µg/mL immediately?
Solution
                    2 /   10  1000  20000   20 L ss D LD C V D µg mL x x µg mg= = = =
Or,  /  2 / 0.1  20 L LD R k D mg= = =
A drug was given to a patient by simultaneous administration of a loading dose of 10 mg and
an infusion rate of 2 mg/hr (the drug has a t½ of 3 hr and a volume of distribution of 10 L)?
What is the concentration of a drug following 6 hr of administration?
Solution
  0.693 / 3  0.231k = =
The concentration of the drug (CP) after 6 hrs = Loading dose (C1) + Concentration by infusion
(C2)
( ) / .  / . 1kt ktP L D DC D V e R V k e- -= + -
( ) ( ) ( ) ( )( )–  0.231  6 –  0.231  6 10  1000 /  10  1000.  2  1000 /  10  1000  0.231 . 1  x xPC x x e x x eé+ -ùû= ë
 0.9 /PC µg ml=
N.B: To determine the concentration of the drug in the body after infusion has been stopped,
first the final concentration of drug at the end of the infusion is to be calculated and considered
as C0. Then, use the IV bolus dose equation (C = C0 e–kt) for calculations for any further point in
time.
A patient was infused for 6 hr with a drug (k = 0.01 hr– 1; VD = 10 L) at a rate of 2 mg/hr. What
is the concentration of the drug in the body 2 hr after cessation of the infusion?
Solution
( ) ( )–  0.01  6 / . 1 –    2  1000 /  10  1000  0.01. 1 –  kt xP DC R V k e x x x e-= =
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( )–  0.06 –  0.06 2 1 –   2  P PC e C e= = -
The obtained value for CP is to be considered the initial concentration of the drug in the plasma
after cessation of the infusion in which the IV bolus equation could be applied:
( )–  0.06 –  0.01  2 .  2 1 –  . o kt xP P PC C e C e e-= =
 1.14 /PC µg ml=
1. A 35-year-old male patient of 80 kg was given a chemotherapeutic agent by IV infusion.
The administered drug has been reported to have an elimination half-life (t ½) of 2 hr, an
apparent volume of distribution of 1.25 L/kg. If the effective plasma concentration of this
drug is 14 mg/l and the drug is commercially supplied in ampoules of 5-mL each con‐
taining 150 mg/mL:
2. What is the recommended starting infusion rate in milligrams per hour and liters per
hour?
3. After the start of the infusion, blood samples were taken from the patient at 12, 16, and 24
hr and the plasma drug concentrations were found to be 16.1, 16.3, and 16.5 mg/L.
Calculate the drug total body clearance ClT in this patient.
4. Considering the data provided above, calculate approximately the elimination half-life
for this antibiotic.
Solution
  0.693 / 2  0.3465k = =
Assume the effective plasma drug concentration is the target drug concentration or CSS:
    14  0.3465  1.5  80  582.1 / ,ss DR C k V x x x mg hr= = =
which is equivalent to 582.1/150 = 3.88 ml, since each ampoule contains 150 mg/ml
It is obvious that the drug has reached a steady plasma level of approximately 16.3 (average
value).
So, Cl =  R / Css =  582.1 /  16.3 =  35.7 L / hr
1     /    35.7 /  1.25  80  0.357 l D DC k V k Cl V k x hr-= = = =
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½  0.693 /  0.357  1.94 t hr= =
4.3. Intravenous Infusion of Two-Compartment Model Drugs
Some drugs such as lidocaine and theophylline when administered by IV infusion do not
follow the one- but rather the two-compartment model. As has been discussed in the IV bolus,
during a constant IV infusion, the drug in the tissue compartment is in distribution equilibrium
with that in the plasma and a steady state concentration is reached during equilibrium.
The mathematical expression that describes the drug plasma concentration is:
( ) ( ) /  1  /  –  /  at btP PC R V k k b a b e a k a b e- -= - - - - -é ùë û
At steady-state (t=α), the last equation could be reduced into:
  / PCss R V k=
N.B: It is not possible to maintain a steady-state stable blood level for a drug that exhibits a
two-compartment model drug following a zero-order rate of infusion. Therefore, a loading
dose is administered to produce an initial plasma level either slightly higher or lower than that
of the desired steady-state level. Several IV bolus injections may be given as short intermittent
IV infusions as a method for administering a loading dose to the patient
4.3.1. Apparent Volume of Distribution at Steady State, Two-Compartment Model
The amount of the drug in the body at steady-state is the product of the plasma concentration
and the steady-state volume of distribution (VD)ss. Assuming equilibrium has been attained
between the central and peripheral compartments:
so, Dtk21 =  DPk12Dt  =  k12DP / k21Dt  =  k12CPVP / k21
At the steady-state, the total amount of drug in the body is equal to the sum of the amount of
drug in tissue (Dt) and central compartment (Dp). Consequently, (VD)SS could be determined
by dividing the total amount of drug in the body by the concentration of drug in the central
compartment at steady-state:
( ) ( ) 12 21   /     /  /  D P t P D P P P P PV ss D D C V ss C V k V C k Cé ùë= + û+ =
( ) 12 21   /D P PV ss V k k V= +
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5. Pharmacokinetics of Drugs Following Oral Absorption
Unlike the process of IV administration, when a drug is introduced into the body by extrava‐
scular route such as oral, intramuscular, subcutaneous, or transdermal administration, an
absorption phase that transfers the drug from the absorption site into the systemic vascular
system must take place. The oral route of drug administration represents the most popular of
the extravascular routes and so, in this chapter, we will focus on its pharmacokinetics;
although, the same principles could be applied for the other extravascular routes. The plasma-
level time curve for drugs administered by intramuscular, subcutaneous, or transdermal
showed the same profile for orally administered drugs. Also, it is important to mention that
for the same route, different drug formulations such as oily, aqueous liquid, suspension,
emulsion, semisolid, fast dissolving tablets, oral disintegrating tablets, or buccal tablets exhibit
the same plasma time curve but with slight modification in the rate and extent of absorption
and/or distribution phases [8]. This concept is common during relative bioavailability study
that involves identification of a significant difference between different pharmaceutical
products administered by the same or another non-intravenous route of administration.
As previously mentioned, the process of gastrointestinal (GIT) absorption is mainly dependent
on physiology and anatomy of the GIT, physicochemical factors of the drug, and dosage-form-
related factors [1, 3].
The process of oral drug absorption (drug input) is mainly first-order, unless it has been verified
experimentally or through the pharmacokinetic models that it is zero-order.
The figure below represents the plasma-level time curve for a drug administered by oral route;
unlike the IV bolus, there is an absorption phase and the overall rate of change in the amount
of the drug in the body dDB/dt is the function of both the rate of drug absorption and elimi‐
nation. The maximum plasma concentration is represented as Cmax, and the time needed to
reach maximum concentration is represented as tmax.
Figure 10. Plasma-level time curve for a drug administered by oral route
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If DGI represents the amount of the drug in the GIT and DE represents the amount of the drug
eliminated, the change in the amount of the drug in the body dDB/dt could be expressed as:
/   /   /B GI EdD dt dD dt dD dt= -
The above curve could be classified into three segments (phases):
• The absorption phase, where the rate of drug absorption (dDGI/dt) is greater than the rate of
drug elimination (dDE/dt)
• The peak drug plasma concentration, in which the rate of drug absorption (dDGI/dt) is equal to
the rate of drug elimination (dDE/dt)
• The elimination phase, when the rate of drug elimination (dDE/dt) is greater than the rate of
drug absorption (dDGI/dt)
It must be noted that, during the absorption phase and once the drug is available in the plasma,
some of the absorbed drug may be eliminated, but absorption is major. Also, during the
elimination phase, some drug may still remain at the absorption site; however, the rate of drug
elimination is higher than the rate of drug absorption until the entire drug at the absorption
site is depleted and hence, dDGI/dt = zero and at this stage dDB/dt = - dDE/dt.
5.1. Zero-Order Absorption Model
It is previously mentioned that the oral drug absorption process is mainly first-order. Zero-
order absorption of drug is expected in two cases:
• Drugs absorbed through carrier-mediated transport
• The absorption of controlled release drug dosage forms
In this process, the drug is absorbed at a constant rate ko and is eliminated by first-order rate
process in a model similar to that of the intravenous infusion.
The mathematical expression for this model is:
d DB / dt  =  ko –  k  DB and d DB / dt  =  ko –  k  VDCP
Integration of the above equation:
( ) /  .  1  k tP o DC k V k e-= -é ùë û
5.2. First-Order Absorption Model
Drugs absorbed by passive diffusion transport mechanism exhibit first-order absorption. Such
behavior is expected from:
• Drugs administered as solution and most suspension
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• Immediate release tablets, capsules, and suppositories
• Intramuscular and subcutaneous aqueous injections
For any orally absorbed drug, if (F) is the fraction of drug absorbed, DGI is the amount of drug
in solution in the GIT at any time (t), ka is the first-order absorption rate constant and k is the
first-order elimination rate constant; therefore:
The rate of drug disappearance from GIT is: d DGI / dt  =  −ka. DGI . F
The rate of first-order elimination process is: d DE / dt  =  −k . DB
The rate of the amount of drug changed in the body is: d DB / dt  =  F . ka. DGI –  k . DB
Since drug absorption is first-order, the amount of drug in the GIT (DGI) at any time t is equal
to Do. e–ka t, in which Do is the dose of drug given.
So,
–  /   . . . –  . ka tB a o BdD dt F k D e k D=
The last equation could be integrated to give the general oral absorption equation as follow:
( ) ( )–  –    . . /  . – . –  k t ka tP a o D aC F k D V k k e e= é ùë û
It must be noted that the value of F may vary from 1 for completely absorbed drug to zero for
drug that is fully unabsorbed.
The time needed to reach the maximum plasma concentration tmax could be calculated by
considering that at Cmax (maximum plasma concentration), the rate of drug absorbed is equal
to the rate of drug eliminated:
/   . . –  .  0B a GI BdD dt F k D k D= =
. .  . a GI BF k D k D=
–  –  . . .  . . o ka t o k taF k D e k D e=
–  –     ka t k tak e k e=
 –      –   a aln k k t ln k k t=
 –      –   a aln k ln k k t k t=
( ) –      –  a aln k ln k t k k=
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( )   –   /  –  a at ln k ln k k k=
( ) 2.303  /   /   max a at log k k k ké ùë û= -
From the above equation, tmax is independent of the dose and is dependent on the rate constants
for absorption (ka) and elimination (k).
The value of Cmax is better to obtain mathematically (kinetically) since measurement of Cmax
may not be possible due to improper timing of the blood samples.
Cmax is determined first; calculate tmax using the last equation:
( ) 2.303  /   /  –  ]max a at log k k k ké ùë û=
Then, use the obtained tmax value and substitute in the CP equation to get Cmax, in which
CP =  F . ka. Do / VD(ka –k )  (e –kt –  e −ka t)
The value for the first-order elimination rate constant (k) could be determined graphically from
the plasma-level time curve after single oral administration, in which at later time, when the
drug absorption has been completed, the value e-ka t ≈ zero and plasma concentration equation
will be:
CP =  F  kaDo / VD(ka –k )  (e –kt),  which is analogue to CP =  CP o. e –kt
And so, log  CP =  log  F . ka. Do / VD(ka –k )  –kt / 2.303
If the log drug plasma concentration is plotted against time, a straight line for the elimination
phase is obtained, from which the slope of the line is –kt/ 2.303
Figure 11. Semi-log plot of plasma concentration against time curve following oral adminstartion.
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The urinary drug excretion data could be used also to determine the first-order elimination
rate constant in the same manner in which the kinetic process could be expressed as:
( ) ( )– –  /   . . . /  –  . –  kt ka tu a e o adD dt F k k D k k e eé ùë û=
A plot of dDu/dt versus time will give a curve similar to the above curve, in which also after
drug absorption has been completed, the value – e–ka t ≈ zero and a straight line for the terminal
part is obtained, from which the slope of the line is –kt/2.303.
5.3. Determination of Absorption Rate Constant (ka); Method of Residual
The value for ka cannot be obtained directly from the plasma-level time curve for the drug
administered by oral route as we calculated the elimination rate constant (k), but it could be
obtained using the method of residuals or a feathering technique, which is illustrated in the
following graph:
1. On a semilog paper, plot the relation between plasma drug concentrations versus time.
2. Extrapolate the linear part of the terminal phase.
3. Identify a minimum of three points on the upper part of the extrapolated line (X1′, X2′,
and X3′).
4. From each identified point, drop a vertical line on the curve to obtain their corresponding
points on the curve (X1, X2, and X3).
5. Plot again the values for the differences (X1′ - X1), (X2′ - X2) and (X3′ - X3) versus time.
6. A straight line will be obtained in which the slope = -ka / 2.303.
Figure 12. The plasma-level time curve for a drug administered by oral route used to determine ka by the method of
residual
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5.4. Lag time
Some physiological factors such as gastric-emptying rate and motility of the intestine may cause
delay in the oral absorption after single oral administration of some drugs in some candidates.
In such case, there is a gap or a delayed period before the appearance of the first-order plasma-
level time curve as shown in the following figure, where the two residual lines obtained by
feathering the oral absorption plasma-level time curve intersect at a point greater than t = 0 on
the x axis.
Figure 13. First-order plasma level time curve showing lag time
The drug plasma concentration can be described in this case as:
( ) ( ) ( )( )–  –    . . / –  –  k t to ka t toP a o D aC F k D V k k e e- -é ùë û=
5.5. Flip-Flop of ka and k
According to the previous discussion for drugs administered by single oral dose, the absorp‐
tion phase is much faster than the elimination phase and so, ka > k. It has been observed with
some drugs such as isoproterenol and salicyluric acid that the elimination rate of these drugs
is much greater than their absorption rate, such drugs exhibit flip-flop phenomenon (reversal
or interchange of the values of the rate constants). To make sure of this behavior, the drug is
administered by oral and IV bolus routes and elimination rate k is calculated for both routes;
then the absorption rate ka is determined for oral route by the method of residual. It will be
obvious that the values for ka and k obtained by the method of residuals have been inter‐
changed. Such behavior is expected from drugs that have a fast elimination rate in which k >
ka and from controlled release products.
5.6. Determination of ka by Plotting Percent of Drug Unabsorbed versus Time (Wagner–Nelson Method)
For any drug administered as a single oral dose (Do), after an elapsed time (t), there will be an
amount unabsorbed or remains in the GIT (DGI), amount will be excreted in the urine (Du) and
an amount will be available in the body plasma (DB); Do =  DGI +  Du +  DB
• The amount of the drug absorbed (Ab) = Du + DB
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• The fraction of the drug remaining (unabsorbed) in the GIT is DGI/Do
The amount of the drug remaining in the GIT (unabsorbed) at any time (t) could be expressed
by:
/    /    GI o GI a odD dt D dD dt k Da =
–   ka tGI oD D e=
–                /   /  . /  2.303ka tGI o GI o aD D e log D D k t= = -
Plotting the fraction of drug unabsorbed versus time in a semilog graph paper will yield a
straight line, the slope of which is ka / 2.303.
5.7. Effect of ka and k on Cmax, tmax, and AUC
It could be asked: Does the change in ka and k affect the values of tmax, Cmax and AUC? The
answer is illustrated in the following figures and it could be explained as follows:
1. If the value for ka increased (0.3 to 0.7/hr) while the elimination rate is kept constant, then
tmax becomes shorter, Cmax increases, and AUC remains constant.
Figure 14. The plasma-level time curve for a drug administered by oral route showing change in ka and k and their
effect on the values of tmax, Cmax and AUC
2. If the absorption rate is kept constant and the elimination rate increases (0.1 to 0.5/hr),
then tmax decreases, Cmax decreases, and AUC decreases.
3. If the values for the absorption rate ka and the elimination rate k are reversed, then the
same tmax is obtained while Cmax and AUC are different.
5.8. Drug Elimination
The process of drug elimination from the body involves two major ways: metabolism/biotrans‐
formation (by the liver) and/or excretion (mostly by the kidney). The rate process for drug
elimination is an overall first-order.
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The high blood supply to the liver, 20% arterial blood directly from the heart and 80% venous
blood from the gastro-intestinal tract through the hepatic-portal vein (first-pass effect), and
the liver microsomal enzymes make the liver the main site for drug metabolism. Oxidation,
reduction, hydrolysis, and conjugation are the four metabolic processes.
Drug excretion is the removal of the drug from the body, which is mainly renal for nonvolatile,
water-soluble, and low molecular weight drugs. Some other routes of drug excretion involve
removal of the drug through bile, sweat, saliva, milk, or other body fluids.
Anatomically, the kidneys are paired retroperitoneal structures with the left kidney located
somewhat more superior in position than the right. The outer zone of the kidney is called the
cortex and the inner is called medulla.
The two kidneys represent about 0.5% of the total body weight, receive approximately 20–25%
of the cardiac output, and serve endocrine and nonendocrine functions. Nonendocrine func‐
tions including filtration and excretion of metabolic waste products (urea and ammonia),
regulation of necessary electrolytes, fluid and acid-base balance. In addition, the kidney has
two endocrine functions: secretion of renin which regulates blood pressure and secretion of
erythropoietin that stimulates red blood cell production.
Figure 15. Structure of nephron
The nephrons are the basic functional units of the kidney responsible for the removal of
metabolic waste and maintenance of water and electrolyte balance. There are 1–1.5 million
nephrons in each kidney.
Each nephron is composed of a renal corpuscle and a renal tubule specialized for reabsorption
and secretion. The renal corpuscle is composed of a glomerulus inside a bowman’s capsule,
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which is the nephron’s initial filtering component. The renal tubule, containing the tubular
fluid filtered through the glomerulus, consists of proximal convoluting tubule, loop of henle
(descending and ascending limb), and distal convoluting tubule. After passing through the
renal tubule, the filtrate continues to the collecting duct, which is not part of the nephrons.
The volume of blood flowing through the kidney (renal vasculature) per unit time is referred
to as the renal blood flow (RBF), which exceeds 1.2 L/min or 1700 L/day, while, the renal plasma
flow (RPF) is the renal blood flow minus the volume of red blood cells.
N.B: Hematocrit (Hct) is the fraction of blood cells in the blood which is about 45% of the total
blood volume.
( )   1RPF RBF Hct= -
The glomerular filtration rate (GFR) in a normal adult male subject is approximately 125 ml/
min, so about 180 L of fluid per day is filtered through the kidney. The average urine volume
is 1–1.5 L, which accounts for the reabsorption of 99% of the fluid volume filtered at the
glomerulus.
5.9. Renal Drug Excretion
The mechanisms of renal drug excretion may include any combination of the following:
1. Glomerular filtration of unbound drug
2. Active tubular secretion of free and protein-bound drug
3. Tubular passive/active reabsorption
Glomerular filtration: Most drugs (ionized or nonionized) are readily filtered from the blood
unless they are tightly bound to large molecules such as plasma protein or have been incor‐
porated into red blood cells. The hydrostatic pressure within the glomerular capillaries is the
major driving force for glomerular filtration. Inulin and creatinine are examples of drugs that
are eliminated by filtration only and that could be used to measure the GFR.
Active tubular secretion: This process involves transport of the drug against a concentration
gradient from the blood capillaries around the nephron to the nephron lumen, which is
characterized by the following: it is carrier-mediated, requires energy, the carrier is saturable,
and competition for the same carrier could occur. Iodopyracet (Diodrast) and p-amino-
hippuric acid (PAH) are common examples of drugs used to measure active tubular secretion,
since both are filtered by the glomeruli and secreted by the tubular cells.
N.B: The process of drug protein binding has very little effect on the elimination t½ of the drug
excreted mostly by active secretion, while for drugs that are excreted only by glomerular
filtration, the elimination half-life may be changed markedly according to the binding affinity
of these drug for plasma proteins. Since drug protein binding is a reversible process, drug
bound to plasma protein rapidly dissociates into a free drug that is secreted by kidneys. This
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behavior is very common for some of the penicillins that are extensively bound to plasma
protein, but their elimination half-lives are short, which could be attributed to rapid elimina‐
tion by active secretion.
Figure 16. Mechanisms of renal drug excretion through nephron
Tubular reabsorption: Drug moves from nephron lumen to blood by passive diffusion (Fick’s
Law is applied) or sometimes by an active process. Most drugs are weak acids or weak bases
and hence the reabsorption of such drugs is influenced by the pH of the renal tubule fluid and
the drug pKa, as both will affect the ratio of dissociated (ionized) to the undissociated
(nonionized). The drug pKa is constant, but the normal urinary pH may vary from 4.5 to 8.0,
depending on diet, pathophysiology, and drug intake. The undissociated drug is easily
reabsorbed from the renal tubule back to the body.
Some drugs such as ascorbic acid and antacids, for example, sodium carbonate, may alter the
urine pH. The former decreases (acidify) while the latter increases (alkalinize) the urinary pH
when administered in large quantities. During excretion of these drug solutions, the urine pH
may drastically change and alter other drug reabsorption and/or excretion by the kidney.
According to the Henderson–Hesselbalch equation, the percent of ionized to nonionized drug
is the function of both pH and pKa, as follows:
For acidic drugs: pH  =  pKa +  log  ionized / unionized
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( ) –  /   10 pH pKaIonized unionizedé =ùë û
( ) –    . 10 pH pKaIonized unionizedé ùë û=
( )*       /    The fraction of acidic drug ionized ionized ionized unionized= +é ùë û
( ) ( ){ } –   –   . 10 /  . 10  pH pKa pH pKaunionized unionized unionizedé ù é ù é ùë û= +ë û ë û
( ) ( ) –   –   10 / 1  10pH pKa pH pKa= +
For basic drugs: pH  =  pKa +  log unionized  ionized
( ) ( ) –   –  *       1  10 / 10pH pKa pH pKaThe fraction of basic drug ionized = +
The urine–plasma (U/P) ratio of weak acidic or basic drugs could be evaluated from the
following:
For weak acids: U / P  =  1 +  10( pH  urine – pKa) / 1 +  10( pH  plasma – pKa)
For weak bases: U / P  =  1 +  10( pKa – pH  urine) / 1 +  10( pKa – pH  plasma)
Example
The pKa of a weak acidic drug is 5. Calculate the U/P at urinary pH of 3, 5, and 7, respectively.
Solution
For acidic drug, U / P  =  1 +  10( pH  urine – pKa) / 1 +  10( pH  plasma – pKa)
At pH = 3 At pH = 5 At pH = 7
U/P = 1/252 U/P = 2/252 U/P = 101/252
5.10. Drug Clearance
As we mentioned for IV bolus administered drugs, Clearance or drug clearance is a pharma‐
cokinetic term describing the process of drug elimination from the body without identifying
the mechanism of this process. It refers to the volume of plasma fluid that is cleared of drug
per unit time (volume approach, L/hr or ml/hr) or the amount of the drug eliminated from the
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body per unit time (mass approach, mg/min or mg/hr). It may also be considered as the fraction
of the drug VD that is excreted by the kidney per unit of time (fraction approach).
Practically, drug clearance (body clearance, total body clearance, or ClT) may also be expressed
based on the plasma drug concentration as the elimination rate of the drug divided by the
plasma drug concentration.
( )  / /  ( )
/  //
T E P
EliminationrateCl dD dt CPlasmaconcentration Cp
µg min ml minµg ml
= =
= =
Since the drug elimination rate is a first-order process, so dDE /dt is equal to k DB or k Cp VD.
 . /  . . /  . T B P P D P DCl k D C k C V C k V= = =
Example
Calculate the elimination rate for penicillin if the plasma drug concentration is 2 µg/ml,
assuming penicillin has a clearance of 15 ml/min.
Solution
    2  15  30 /P TElimination rate C xCl x µg min= = =
Using the previous penicillin example, assume that the plasma penicillin concentration is 10
µg/ml. Calculate the rate of drug elimination.
/  10  15  150  /EdD dt x µg min= =
Example
A 70-kg male patient has been administered a single oral dose of an antimalarial drug as a
prophylactic treatment. If this drug has an elimination half-life of 3 hr and an apparent volume
of distribution of 100 mL/kg, assuming that this drug follows a one-compartment kinetic
model, determine the drug total body clearance in this patient.
Solution
1
½  0.693 /  0.693 / 3  0.231 k t hr-= = =
CT =  k  VD =  0.231 x 100 =  23.1 ml / kg  hr  and for 70 kg, ClT =  23.1 x 70 =  1617 ml / hr
Pharmacokinetics of Drugs Following IV Bolus, IV Infusion, and Oral Administration
http://dx.doi.org/10.5772/61573
91
5.11. Physiologic/Organ Clearance
This term deals with any individual organ or tissue group involved in the process of drug
removal from the body. If Q is the blood flow through this organ, Ca is the concentration of
drug entering the organ (usually arterial drug concentration), Cv is the drug concentration
leaving the organ (venous drug concentration), so the diagram that best describes this process
will be:
Q Ca  Q CV 
Elimination Drug 
Elimination Organ 
Figure 17. Diagram that best describes the process of physiologic/Organ Clearance
Accordingly, the physiologic/organ clearance may be described as the blood volume fraction
which contains a specific drug that flows through the organ and is eliminated of this drug per unit
time. Accordingly, clearance is considered as the product of the blood flow (Q) to the organ,
and the extraction ratio (ER):
Clearance = Q. (ER)
ER is the fraction of drug extracted by the organ as drug passes through and is equal Ca –
CV divided by the entering drug concentration Ca, i.e., ER =  (Ca –  CV ) /  Ca
( )  .  –  /VCl Q Ca C Ca= é ùë û
It must be noted that clearance measurements using the physiologic approach require
measurements of blood flow and extraction ratio to a specified organ or group of tissue, which
is not so easy, and invasive techniques are needed to obtain these data.
5.12. Model-Independent Methods
These are noncompartment model approaches that help to determine certain pharmacokinetic
parameters such as drug clearance and bioavailability (F). In these methods, no assumption
for a specific compartment model is required to evaluate the data, which is the major advantage
of these methods. In addition, no complicated methods are required to determine the studied
pharmacokinetic parameters such as the volume of distribution and the elimination rate
constant. These parameters can be calculated directly from the equation that best fits the
plasma-drug-concentration time curve.
Clearance can be estimated directly from the plasma–time concentration curve by:
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0  oCl D AUC
aé ùë û=
where Do is the dose and AUC 0α =  t0αCPdt .
Since AUC 0α is calculated from the plasma-level time curve from 0 to infinity by the trape‐
zoidal rule, no compartmental model is assumed.
In summary, clearances may be expressed mathematically as:
 
  ( )
. /  . . /  . 
T
B P P D P D
EliminationrateCl Plasmaconcentration Cp
k D C k C V C k V
=
= = =
( ) ( )Physiologic or organ clearance       –  /Q ER Q Ca Cv Ca= = é ùë û
0Noncompartmental clearance  /Do AUC
aé ùû= ë
5.13. Renal Clearance
Renal clearance utilizes the same concept for the clearance or the drug clearance previously
illustrated, except that the drug is cleared by the kidney and so the volume, mass, or fraction
approaches are also applicable here. It could be expressed also as the urinary drug excretion
rate (dDu/dt) divided by the plasma drug concentration:
( )  /    /  /  RCl excretion rate plasma concentration dDu dt Cp= =
For any drug cleared by the kidney, the rate of drug passing through the kidney must equal
the rate of drug excreted in the urine.
   R P u uCl x C Q x C=
where ClR is renal clearance, Cp is plasma drug concentration, Qu is the rate of urine flow, and
Cu is the urine drug concentration.
  /   /R u u P PCl Q x C C excretion rate C= =
5.14. Excretion Mechanism (Comparison of Drug Excretion Methods)
Since the renal excretion is the urinary drug excretion rate (dDu/dt) divided by the plasma
drug concentration, the expression could be rephrased to include the drug excretion mecha‐
nisms as follows:
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( )
  /  
          /
R
P
Cl excretion rate plasma concentration
Glomerular filtration rate tubular secretion rate tubular reabsorption rate C
= =
+ -
The excretion mechanism could be identified if the clearance value of the drug is compared to
a well-recognized standard reference such as Inulin, which is a substance completely cleared
through glomerular filtration only (clearance ratio). The following table illustrates identifica‐
tion of the mechanism:
Clearance Ratio Renal Excretion Mechanism
Cl drug/Cl Inulin < 1 Drug is subjected to tubular reabsorption
Cl drug/Cl Inulin = 1 Drug is filtered only
Cl drug/Cl Inulin > 1 Drug is subjected to active tubular secretion
Example
If glomerular filtration at rate 125 ml/min is the sole elimination mechanism for gentamicin
and kanamycin from the body, assuming gentamicin and kanamycin have VD of 10 and 20 L,
respectively, is there a difference in the drug clearances for each drug based on the classic and
physiologic approaches? If not, describe pharmacokinetic parameters that could be used to
differentiate between the two drugs.
Solution
Since the two drugs are eliminated from the body by glomerular filtration only, the classic and
physiologic approaches will be the same and equal 125 ml/min.
For gentamicin: k = Cl/VD = 125/10000 = 0.0125 min-1 and t½ = 0.693/0.0125 = 55.44 min,
while for kanamycin: k = 125/20000 = 0.00625 min-1 and t½ = 0.693/0.00625 = 110.88 min.
So, there is an obvious difference between the elimination rate and half-life of the two drugs,
although both have similar drug clearance.
5.15. Determination of Renal Clearance by Graphical Methods
It is possible to determine the renal clearance graphically by two methods:
1. If after administration of a drug, the drug excretion rate (dDu/dt) versus the plasma
concentration (Cp) is plotted, the drug excretion rate is the slope of the curve, since
ClR = excretion rate/plasma concentration, but we must note that the slope will be large for
drug that is excreted rapidly and will be of small value for drug that is excreted slowly through
the kidney, i.e., the slope is smaller.
( )     / / PSlope renal clearance dDu dt C= =
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Figure 18. A plot of the drug excretion rate (dDu/dt) versus the plasmaconcentration (Cp)
2. Since the renal clearance ClR =  (dDu / dt) / CP , so ClR.CP =  dDu / dt
Rearranging and integration of the last equation will give:
    So,  t t tDuo R Ro oodDu Cl Cp dt Du Cl AUCé ù é ùë û ë= = ûò ò
If a graph were plotted of the cumulative drug excreted in the urine versus the area under the
plasma-level time curve, renal clearance is the slope of the curve.
By plotting cumulative drug excreted in the urine from t1 to t2, [Du]t2 t1 versus [AUC] t2 t1, an
equation similar to that previously mentioned could be obtained, in which the slope is equal
to the renal clearance: Du t 2t1 =  ClR AUC t 2t1
Figure 19. A plot of the cumulative drug excreted in the urine versus the area under the plasma-level time curve
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Important Considerations
1. Body clearance (ClT), renal clearance (ClR), and hepatic clearance (Clh) can be calculated
according to the following expressions:
 .   .  . T D R D h DCl k V Cl ke V Cl km V= = =
2. Total body clearance (ClT) is equal to the sum of renal clearance and hepatic clearance:
          T R h D D DCl Cl Cl k V ke V km V k ke km= + = + = +
5.16. Fraction of Drug Excreted
The fraction of drug excreted unchanged in the urine (fe) is equal to the ratio of the total amount
of unchanged drug excreted in the urine Dαu, to the fraction of the dose absorbed, FD0:
0/e uf D FDa=
It was found that (fe) is also equal to ke/k: f e = D αu /  F D0 =  ke / k
Problem
I) A single oral dose of antibiotic (500 mg) was given. The drug is 90% systemically available.
The total amount of unchanged drug recovered in the urine was found to be 300 mg, and the
total amount of metabolite recovered in the urine was 150 mg. The drug has an elimination
half-life of 3.3 hr and its apparent volume of distribution is 1000 ml. Calculate the total body
clearance, renal clearance, and nonrenal clearance.
Solution
1. k  =  0.693 / 3.3 =  0.21 h r −1ClT =  k  VDClT =  0.21 x 1000 =  210 mL / hr
2. Since, ke / k  = D αu /  FDo  ke =  (300 / 450)(0.21) =  0.14 h r −1
   0.14  1000  140 /R DCl ke V x mL hr= = =
3. Clh =ClT −ClR                         Clh =  210 –  140 =  70 mL  /  hr
II) An analgesic drug was given to an elderly patient by IV bolus injection at a dose of 500 mg.
The apparent volume of distribution and the elimination half-life of this drug were estimated
to be 21 L and 6 hr, respectively. Urine samples were collected from the patient for 48 hr, and
the amount of unchanged drug recovered was found to be 400 mg. Determine the fraction of
the dose excreted unchanged from this drug in the urine. Calculate k, ke, ClT, ClR, and Clh.
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Solution
1 400 / 500  0.8   0.693 / 6  0.1155 ef k hr-= = = =
1    0.8  0.115  0.0924 
   0.1155  21  2.34 /
   0.0924  21  1.94 /
 2.34 –  1.94  0.49 /
e
T D
R D
h T R
ke f k x hr
Cl k V x L hr
Cl ke V x L hr
Cl Cl Cl L hr
-= = =
= = =
= = =
= - = =
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